# US 2024/0197799 A1 · Ganoderma lucidum spore oil and use thereof in preparation of anti-cancer-related fatigue medicaments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197799 A1
- Document ID: US20240197799A1
- Status: Published application
- Kind: A1
- Application number: 18/415,519
- Filed: 2024-01-17
- Published: 2024-06-20
- Earliest claimed: 2021-07-22
- Assignees: Guangzhou Hanfang Pharmaceutical Co., Ltd.
- Applicants: Guangzhou Hanfang Pharmaceutical Co., Ltd.
- Inventors: Juyan Liu; Wendong Xu; Hongfei Cai; Jing Li; Cheng Yuan; Yaming Han; Lin Cao; Shunzhi Tang; Yukang Mao; Guocai Wang; Qin Zhang
- Web page: https://patentgrep.com/patent/US20240197799A1

## CPC

- A61K 36/074: Ganoderma
- A61P 35/00: Antineoplastic agents
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0031: {Rectum, anus}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/215: of carboxylic acids
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 37/04: Immunostimulants
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2236/15: involving mechanical treatment, e.g. chopping up, cutting or grinding
- A61K 2236/37: Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
- A61K 2236/51: Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
- Y02P 20/54: using solvents, e.g. supercritical solvents or ionic liquids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Ganoderma lucidum spore oil and use thereof in the preparation of anti-cancer-related fatigue medicaments are provided. The content of triglycerides in the Ganoderma lucidum spore oil is greater than 90%. Ganoderma lucidum triterpenoids are not detected. The Ganoderma lucidum spore oil is extracted by means of supercritical CO2, eluted with a silica gel column and a mixed solution of petroleum ether-ethyl acetate, concentrated under reduced pressure and vacuum-dried. The Ganoderma lucidum spore oil is highly effective in mitigating cancer-related fatigue, has good safety, and can be used in the preparation of medicaments for treating cancer-related fatigue.

## Claims

### Claim 1

A method for preventing or treating cancer-related fatigue, comprising administering to a subject a therapeutically effective amount of Ganoderma lucidum spore oil, wherein no Ganoderma lucidum triterpenoids are detected in the Ganoderma lucidum spore oil.

### Claim 2 (depends on 1)

The method according to claim 1, wherein a content of triglyceride ingredients is greater than 90% in the Ganoderma lucidum spore oil.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the Ganoderma lucidum spore oil is prepared by following steps:
A. making Ganoderma lucidum spores subjected to wall-breaking, granulation, drying, and supercritical CO2 extraction to provide a spore oil crude product;
B. dissolving an appropriate amount of silica gel in a mixed solution of petroleum ether and ethyl acetate, preparing a column with the silica gel in the mixed solution to provide an elution column; and
C. loading the spore oil crude product onto the elution column, eluting with the mixed solution of petroleum ether and ethyl acetate under normal pressure, collecting and combining eluents, concentrating under reduced pressure to remove solvents, and vacuum-drying, to provide the Ganoderma lucidum spore oil.

### Claim 4 (depends on 3)

The method according to claim 3, wherein a mass ratio of the spore oil crude product to the silica gel is 1:10-40.

### Claim 5 (depends on 3)

The method according to claim 3, wherein in the mixed solution of petroleum ether and ethyl acetate, a volume ratio of petroleum ether to ethyl acetate is 8.5-9.5:0.5-1.5.

### Claim 6 (depends on 5)

The method according to claim 5, wherein in the mixed solution of petroleum ether and ethyl acetate, the volume ratio of petroleum ether to ethyl acetate is 9.2:0.8.

### Claim 7 (depends on 3)

The method according to claim 3, wherein a ratio of diameter to height of the elution column is 1:10-20.

### Claim 8

Use of Ganoderma lucidum spore oil in preparation of an anti-cancer-related fatigue medicament, wherein no Ganoderma lucidum triterpenoids are detected in the Ganoderma lucidum spore oil.

### Claim 9

A medicament comprising Ganoderma lucidum spore oil, wherein no Ganoderma lucidum triterpenoids are detected in the Ganoderma lucidum spore oil, and the medicament further comprises a pharmaceutically acceptable carrier.

### Claim 10 (depends on 9)

The medicament comprising the Ganoderma lucidum spore oil according to claim 9, wherein the medicament is one of tablet, capsule, oral absorbent, granule, electuary, pill, pulvis, ointment, pellet, suspension, solution, injection, suppository, cream, spray, drops or patch.